• Home
  • Thesis paper
  • Seelos Therapeutics to Host Research and Development Update Conference Call and Webcast on December 15, 2022

Seelos Therapeutics to Host Research and Development Update Conference Call and Webcast on December 15, 2022

By on November 23, 2022 0

NEW YORK, November 23, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, today announced that it will hold a Research and Development Update Conference Call and Webcast on Thursday, December 15e of 1-3 p.m. ET.

“As we approach what we believe will be a very important and catalytic year 2023 for Seelos, it is important that we update our investors on our progress and strategic plans,” said Raj Mehra Ph.D., Chairman- CEO of Seelos. . “We have made great progress with our 3 ongoing registration studies, performed insightful market research, and will publish and discuss exciting and encouraging preclinical data.”

During the call, members of Seelos’ senior management, in collaboration with several Key Opinion Leaders (KOLs), will provide updates on ongoing clinical studies, additional new preclinical data, recently completed contracts and an overview of the company’s strategic plans in its portfolio. clinical and pre-clinical stage programs.

Registration is available at https://lifescievents.com/event/seelos-therapeutics-kol-event/and an updated call itinerary will be published a few days before the call and available at http://seelostherapeutics.com.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapies to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. . The company’s strong portfolio includes several late-stage clinical assets targeting indications such as acute suicidal ideation and behavior (ASIB) in major depressive disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington disease, Alzheimer’s disease and Parkinson’s disease.

For more information, please visit our website: http://seelostherapeutics.comthe contents of which are not incorporated herein by reference.

Forward-looking statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor under the Private Securities Litigation Reform Act of 1995. Such statements include, among other things, those regarding the Seelos’ anticipated timeline for releasing new preclinical data, topics expected to be discussed on the call, and the expectation that 2023 will be a catalyst-rich year. These statements are based on Seelos’ current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks associated with Seelos’ business include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies and not obtaining marketing authorizations for its product candidates, the risk that prior clinical results will not be replicated in future studies and clinical trials, the risks that the results of clinical studies will not meet all or part of the endpoints of a clinical study and that the data generated from these studies may not support a regulatory submission or approval, the risks associated with implementing a new business strategy, the risks associated with raising capital to fund its development plans and ongoing operations, the risks associated current share price of Seelos, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos’ periodic filings with Secu rities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove to be correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if we subsequently make them available on our website or otherwise. We undertake no obligation to update, modify or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Contact information:

Antoine Marciano
Head of Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2n/a Floor
New York, NY 10022
(646) 293-2136
[email protected]

mike moyer
General director
LifeSci Advisors, LLC
250 West 55th Street, Suite 3401
New York, NY 10019
(617) 308-4306
[email protected]

SOURCE Seelos Therapeutics, Inc.